Hyperion Therapeutics Release: HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy

Published: Nov 12, 2012

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the Phase 2 HALT-HE Study were presented at the Presidential Plenary Session I of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver MeetingĀ®), in Boston, MA.

Back to news